 phase II study idarubicin treatment measurable gastric cancer Idarubicin new anthracycline analogues therapeutic index doxorubicin daunorubicin variety murine leukemias solid tumors authors multicenter Phase II trial idarubicin patients advanced gastric cancer Seventeen patients measurable metastatic disease trial idarubicin dose dose toxicity documented responses dose-limiting toxicity myelosuppression data data doxorubicin treatment gastric carcinoma conclusion idarubicin minimal activity treatment gastric carcinoma